Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) EBT: 2011-2024

Historic EBT for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $125.7 million.

  • Adma Biologics' EBT rose 29.30% to $47.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.8 million, marking a year-over-year increase of 112.35%. This contributed to the annual value of $125.7 million for FY2024, which is 545.18% up from last year.
  • As of FY2024, Adma Biologics' EBT stood at $125.7 million, which was up 545.18% from -$28.2 million recorded in FY2023.
  • Adma Biologics' 5-year EBT high stood at $125.7 million for FY2024, and its period low was -$76.6 million during FY2020.
  • Over the past 3 years, Adma Biologics' median EBT value was -$28.2 million (recorded in 2023), while the average stood at $10.5 million.
  • Data for Adma Biologics' EBT shows a peak YoY surged of 545.18% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Adma Biologics' EBT stood at -$76.6 million in 2020, then rose by 6.81% to -$71.4 million in 2021, then rose by 7.69% to -$65.9 million in 2022, then spiked by 57.15% to -$28.2 million in 2023, then soared by 545.18% to $125.7 million in 2024.